Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Stanton, Sasha E ^a   Eary, Janet F ^b   Marzbani, Edmond A ^a   Mankoff, David ^c   Salazar, Lupe G ^a   Higgins, Doreen ^a   Childs, Jennifer ^a   Reichow, Jessica ^a   Dang, Yushe ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive T cell therapy; Breast cancer; FDG; HER2; Indium 111 labeled; PET CT; SPECT

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE; GAMMA INTERFERON; INTERLEUKIN 2;

ARTICLE; BREAST CANCER; CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VIVO STUDY; LEUKAPHERESIS; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PET-CT SCANNER; PRIORITY JOURNAL; SPECT SCANNER; T LYMPHOCYTE;

EID: 84997545208     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0131-3     Document Type: Article

References (11)

1. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116.
3. Disis ML, Dang Y, Coveler AL, Marzbani E, Kou ZC, Childs JS, et al. HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother. 2014;63(2):101-9. doi: 10.1007/s00262-013-1489-4.
4. Abastado JP. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res. 2012;72(9):2159-61. doi: 10.1158/0008-5472.CAN-11-3538.
5. Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nahrig J, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 2008;57(2):271-80. doi: 10.1007/s00262-007-0355-7.
6. Schauwecker DS, Burt RW, Park HM, Mock BH, Tobolski MM, Yu PL, et al. Comparison of purified indium-111 granulocytes and indium-111 mixed leukocytes for imaging of infections. J Nucl Med. 1988;29(1):23-5.
7. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer. 2013;19(6):1525-33. doi: 10.1158/1078-0432.CCR-12-1879.
8. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170(4):2161-9.
9. Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, et al. Serial 2-[18 F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105(1):87-94. doi: 10.1007/s10549-006-9435-1.
10. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23(35):8942-9. doi: 10.1200/JCO.2005.02.6195.
11. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20(11):2624-32.